Aim: To investigate the possible changes in the renal tubular function in severe short-term hypothyroidism using 99mTc-MAG3 renography. Methods: 27 consecutive thyroidectomized patients (7 males and 20 females) aged 19–79 (mean 53) years were included in the present study. 99mTc-MAG3 renography was performed in all patients before and after thyroid hormone replacement therapy. In addition, 51Cr-EDTA clearance and serum creatinine concentrations were determined. Results: The serum creatinine concentrations were significantly increased in hypothyroidism as compared with the concentrations after thyroxine substitution (1.30 ± 0.44 vs. 1.04 ± 0.32 mg/dl, p < 0.05). According to the 51Cr-EDTA clearance, the glomerular filtration rate was significantly lower in hypothyroidism than after treatment (61 ± 18 vs. 75 ± 23 ml/min). In contrast, we did not find any significant change in the renographic parameters for 99mTc-MAG3 before and after treatment (total excreted activity 20 min after administration 51 ± 12 vs. 54 ± 14%; Tmax left:right 4.2 ± 1.77 : 3.91 ± 1.06 min vs. 4.1 ± 1.66 : 4.4 ± 1.96 min). Conclusions: We did not find any influence of thyroid hormones on the outcome of 99m Tc-MAG3 renography. As 99mTc-MAG3 reflects the tubular function, it seems that the renal hemodynamic changes in severe hypothyroidism mainly affect the glomerular function. In general, the glomerular filtration rate reduction seems to be reversible after hormone substitution therapy; however, care has to be taken in patients with renal insufficiency.

Keywords:
Hypothyroidism, renal function studies, Isotopic renal function studies, hypothyroidism, Thyroid hormone replacement therapy, renal function
1.
Hierholzer K, Finke R: Myxedema. Kidney Int 1997;59:82–89.
2.
Salomon MI, Di Scala V, Grishman E, Brener J, Churg J: Renal lesions in hypothyroidism: A study based on kidney biopsies. Metabolism 1967;16:846–852.
3.
Derubertis FR, Michelis MF, Bloom ME, Mintz DH, Field JB, Davis BB: Impaired water excretion in myxedema. Am J Med 1971;51:41–53.
4.
Montenegro J, Gonzalez O, Saracho R, Aguirre R, Gonzalez O, Martinez I: Changes in renal function in primary hypothyroidism. Am J Kidney Dis 1996;27:195–198.
5.
Gillum DM, Falk SA, Hammond WS, Conger JD: Glomerular dynamics in the hypothyroid rat and the role of the renin-angiotensin system. Am J Physiol 1987;253:F170–F179.
6.
Bradley SE, Stephan F, Coelho JB, Reville P: The thyroid and the kidney. Kidney Int 1974;6:346–365.
7.
Katz AI, Emmanouel DS, Lindheimer MD: Thyroid hormone and the kidney. Nephron 1975;15:223–249.
8.
Hlad CJ, Bricker NS: Renal function and I-131 clearance in hyperthyroidism and myxedema. J Clin Endocrinol Metab 1954;14:1539–1550.
9.
Yount E, Little JM: Renal clearance in patients with myxedema. J Clin Endocrinol Metab 1955;15:343–346.
10.
Ford RV, Owens JC, Curd GW, Moyer JH, Spurr CL: Kidney function in various thyroid states. J Clin Endocrinol Metab 1961;21:548–553.
11.
Capasso G, De Tommaso G, Pica A, Anastasio P, Capasso J, Kinne R, De Santo NG: Effects of thyroid hormones on heart and kidney functions. Miner Electrolyte Metab 1999;25:56–64.
12.
Villabona C, Sahun M, Roca M, Mora J, Gomez N, Gomez JM, Puchal R, Soler J: Blood volumes and renal function in overt and subclinical primary hypothyroidism. Am J Med Sci 1999;318:277–280.
13.
Moses MA, Scheinman SJ: The kidneys and electrolyte metabolism in hypothyroidism; in Braverman LE, Utiger Rd (eds): Werner and Ingbar’s The Thyroid, ed 7. Philadelphia, Lippincott-Raven, 1996, pp 812–815.
14.
Graettinger JS, Muenster JJ, Checchia BJ: A correlation of clinical hemodynamic studies in patients with hypothyroidism. J Clin Invest 1957;37:502–510.
15.
Kreisman SH, Hennessey JV: Consistent reversible elevations of serum creatinine levels in severe hypothyroidism. Arch Intern Med 1999;159:79–82.
16.
Fritzberg AR, Kasina S, Eshima D, Johnson DL: Synthesis and biological evaluation of technetium-99m-MAG3 as a hippuran replacement. J Nucl Med 1986;27:111–116.
17.
Taylor A Jr, Eshima D, Fritzberg AR, Christian PE, Kasina S: Comparison of iodine-131 OIH and technetium-99m MAG3 renal imaging in volunteers. J Nucl Med 1986;27:795–803.
18.
Russell CD, Thorstad B, Yester MV, Stutzman M, Baker T, Dubovsky EV: Comparison of technetium-99m MAG3 with iodine-131 hippuran by a simultaneous dual channel technique. J Nucl Med 1988;29:1189–1193.
19.
Fommei E, Ghione S, Hilson AJ: Captopril radionuclide test in renovascular hypertension: A European multicentre study. Eur J Nucl Med 1993;20:617–623.
20.
Brochner-Mortensen J, Rodbrø P: Selection of routine method for determination of glomerular filtration rate in adult patients. Scand J Clin Lab Invest 1976;36:35–43.
21.
Discala VA, Kinney MJ: Effects of myxedema on the renal diluting and concentrating mechanism. Am J Med 1971;50:325–335.
22.
Chertow BS, Motto GS, Shah JH: A biochemical profile of abnormalities in hypothyroidism. Am J Clin Pathol 1974;61:785–788.
23.
Woodrow G, Brownjohn AM, Turney JH: Acute-on-chronic renal failure and hyponatraemia associated with severe hypothyroidism. Nephrol Dial Transplant 1993;8:557–559.
24.
Steiger MJ, Watson AR, Morgan AG: Hypothyroidism and renal impairment. J R Soc Med 1991;84:688–689.
25.
Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, Wondisford FE, Davies TF, DeGroot LJ, Daniels GH, Ross DS, Weintraub BD: Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997;337:888–896.
26.
Lafayette RA, Costa ME, King AJ: Increased serum creatinine in the absence of renal failure in profound hypothyroidism. Am J Med 1994;96:298–299.
27.
Handa SI, Freestone S: Mefenamic acid-induced neutropenia and renal failure in elderly females with hypothyroidism. Postgrad Med J 1990;66:557–559.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.